In a patient with heart failure with reduced ejection fraction and atrial fibrillation who is taking bisoprolol 10 mg daily, has a heart rate of 70–80 bpm and remains hypertensive, should the bisoprolol dose be increased?

Do Not Increase Bisoprolol for Hypertension in This Patient

In a patient with HFrEF and atrial fibrillation already on bisoprolol 10 mg daily (the guideline-recommended target dose) with adequate heart rate control (70-80 bpm), do not increase bisoprolol further to treat hypertension—instead, add or optimize other guideline-directed medical therapies (GDMT) for HFrEF that also lower blood pressure.

Rationale

Bisoprolol is Already at Target Dose

Your patient is receiving bisoprolol 10 mg once daily, which is the evidence-based target dose for HFrEF established in clinical trials 1, 2. The 2022 AHA/ACC/HFSA guidelines explicitly state that the target dose for bisoprolol in HFrEF is 10 mg once daily, with a mean achieved dose in trials of 8.6 mg daily 1. Exceeding this dose moves beyond the evidence base that demonstrated mortality reduction (34% relative risk reduction in all-cause mortality with beta-blockers) 1.

Heart Rate is Appropriately Controlled

The heart rate of 70-80 bpm indicates adequate beta-blockade. While lower heart rates may confer additional benefit in sinus rhythm 3, in atrial fibrillation the benefit of bisoprolol is questionable or absent 3. The CIBIS II post-hoc analysis showed bisoprolol reduced mortality in patients with sinus rhythm (relative risk 0.58, p<0.001) but not in those with atrial fibrillation (relative risk 1.16, p=NS) 3. Your patient's HR is already well-controlled for rate management in AF.

Beta-Blockers Are Not Primary Antihypertensives in HFrEF

Beta-blockers in HFrEF are dosed to target doses proven to reduce mortality, not titrated to blood pressure endpoints. The FDA label confirms bisoprolol's cardioselective properties are maintained at therapeutic doses (≤20 mg), but doses above 20 mg lose beta-1 selectivity and increase risk of bronchospasm and other adverse effects 4. More importantly, increasing beyond the evidence-based target dose of 10 mg provides no proven mortality benefit and risks bradycardia, hypotension, and heart failure decompensation 4.

What to Do Instead: Optimize Other GDMT

Add or uptitrate other HFrEF medications that provide mortality benefit AND blood pressure reduction:

First Priority: SGLT2 Inhibitors

• Add dapagliflozin 10 mg daily or empagliflozin 10 mg daily if not already prescribed 1, 2
• These provide 17% relative risk reduction in all-cause mortality and modest BP reduction
• No titration needed—start at target dose

Second Priority: ARNI or ACEi/ARB

• If on ACEi/ARB, consider switching to sacubitril/valsartan (start 24/26 mg or 49/51 mg twice daily, target 97/103 mg twice daily) 1, 2
• ARNIs provide additional 16% mortality reduction beyond ACEi and significant BP lowering
• If already on ARNI, ensure uptitrated to target dose

Third Priority: Mineralocorticoid Receptor Antagonists

• Ensure spironolactone 25-50 mg daily or eplerenone 50 mg daily is prescribed 1, 2
• These provide 30% relative risk reduction in mortality and BP reduction
• Check potassium and renal function

Fourth Priority: Hydralazine-Isosorbide Dinitrate

• If patient is African American or has contraindications to ARNI/ACEi/ARB, add hydralazine 75 mg three times daily plus isosorbide dinitrate 40 mg three times daily (or fixed-dose combination) 1, 2
• Provides 43% mortality reduction in African Americans and direct vasodilation for BP control

Common Pitfalls to Avoid

1. Do not exceed evidence-based target doses of beta-blockers seeking additional BP control—this abandons the proven mortality benefit and increases adverse effects
2. Do not assume beta-blockers in HFrEF work the same as in hypertension—they are dosed to trial-proven targets, not to BP goals
3. Remember that AF patients may not derive the same beta-blocker mortality benefit as those in sinus rhythm 3, making it even less appropriate to push doses higher
4. Wide pharmacokinetic variability exists with bisoprolol 5—patients with reduced cardiac or renal function achieve higher drug concentrations at the same dose, increasing overdose risk

Monitoring Considerations

• Assess for symptoms of beta-blocker excess: excessive bradycardia (<50 bpm at rest), symptomatic hypotension, fatigue, or HF decompensation 4
• In patients with AF and HFrEF, achieving target doses of all GDMT medications (not just beta-blockers) is associated with significantly better outcomes—30% lower all-cause mortality and 40% lower cardiovascular death/HF hospitalization 6
• Baseline renal function affects GDMT optimization rates—lower eGFR predicts lower achievement of target GDMT 6